FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
Pfizer announced FDA approval for IBRANCE in combination with anti-HER2 therapy for the maintenance treatment of HR+, HER2+ metastatic breast cancer. The approval is supported by Phase 3 PATINA trial data, which demonstrated a 24% reduction in the risk of disease progression or death compared to anti-HER2 and endocrine therapy alone.
Key figures
- Drug Name
- IBRANCE (palbociclib)
- Phase Of Trial
- Phase 3
- Risk reduction
- 24%
- Subtype prevalence
- Approximately 10%
- Patients prescribed historically
- >900,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.